This response to our article addresses an interesting point. Prophylactic treatment with rFVIIa was found to be ineffective in some surgical settings, where major bleeding was not the rule. Of course, every randomized controlled trial (RCT) needs adequate power to detect significant differences between treatment and control groups. In this case, the outcome variables usually considered are (1) the allogeneic blood-product transfusion rate, (2) the amount of allogeneic blood products used, and (3) the amount of perioperative bleeding.
Ranucci M. Administration of Recombinant Activated Factor VII in Major Thoracic Operations—Reply. Arch Surg. 2008;143(10):1021. doi:10.1001/archsurg.143.10.1021-b
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.